Most Read This Week
- Level of Protection Against Reinfection With SARS-CoV-2
- Neratinib Plus Fulvestrant for HER2 Mutant, Non-Amplified Metastatic Breast Cancer
- Chronic Immune-Related AEs After Adjuvant Anti–PD-1 for High-Risk Resected Melanoma
- Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden
- Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases
Recently Updated
- Two Doses of the COVID-19 Vaccine BNT162b2 Are Required for Patients With Cancer
- Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer
- Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- Brentuximab Vedotin With Chemotherapy in Early-Stage, Unfavorable-Risk Hodgkin Lymphoma